Neogenomics Inc. (NEO) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Neogenomics’s revenue went from $232M in fiscal 2016 to $727M in fiscal 2025, growth of about 13.5% a year.
Net income in fiscal 2025 was -$108M, a net margin of -14.9%; the best year in this period was 2019 with $8M.
Over the twelve months to September 30, 2026, revenue was $788M and net income -$32M.
Free cash flow was -$22M in fiscal 2025 and positive in 4 of the 10 years shown.
The diluted share count rose 65% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $788M | $727M | $661M | $592M | $510M | $484M | $444M | $409M | $277M | $240M | $232M |
| Gross profit | $353M | $314M | $290M | $245M | $188M | $187M | $186M | $197M | $127M | $102M | $98M |
| Operating income | -$49M | -$116M | -$92M | -$108M | -$158M | -$119M | -$14M | $13M | $10M | $3M | $2M |
| Net income | -$32M | -$108M | -$79M | -$88M | -$144M | -$8M | $4M | $8M | $3M | -$396000 | -$6M |
| EPS (diluted) | $-0.24 | $-0.84 | $-0.62 | $-0.70 | $-1.16 | $-0.07 | $0.04 | $0.08 | $0.07 | $-0.14 | $-0.40 |
| R&D | $39M | $37M | $31M | $27M | $30M | $22M | $8M | $8M | $3M | $4M | $5M |
| Revenue growth | — | +10.1% | +11.7% | +16.1% | +5.2% | +9.0% | +8.7% | +47.7% | +15.2% | +3.6% | +4536.2% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4M | $5M | $7M | -$2M | -$66M | -$27M | $1M | $23M | $45M | $18M | $21M |
| Capital spending | -$33M | -$27M | -$41M | -$29M | -$31M | -$64M | -$29M | -$20M | -$14M | -$14M | -$8M |
| Free cash flow | -$29M | -$22M | -$34M | -$31M | -$97M | -$91M | -$28M | $3M | $30M | $4M | $14M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based pay | $35M | $41M | $33M | $25M | $25M | $22M | $10M | $10M | $7M | $6M | $5M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $160M | $367M | $342M | $263M | $515M | $296M | $173M | $10M | $13M | $13M |
| Debt | — | $409M | $605M | $612M | $611M | $613M | $216M | $127M | $124M | $108M | $109M |
| Equity | — | $837M | $902M | $942M | $998M | $1.1B | $694M | $507M | $320M | $172M | $162M |
| Total assets | — | $1.4B | $1.6B | $1.7B | $1.7B | $1.9B | $988M | $710M | $505M | $344M | $337M |
| Shares (diluted) | 129M | 128M | 127M | 126M | 124M | 120M | 112M | 104M | 92M | 79M | 78M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 44.8% | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | 46.0% | 42.4% | 42.3% |
| Operating margin | -6.3% | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | 3.6% | 1.2% | 0.9% |
| Net margin | -4.1% | -14.8% | -11.9% | -14.9% | -28.3% | -1.7% | 0.9% | 2.0% | 0.9% | -0.2% | -2.6% |
| FCF margin | -3.6% | -3.0% | -5.1% | -5.2% | -19.0% | -18.8% | -6.2% | 0.8% | 11.0% | 1.8% | 6.0% |
| ROIC | — | -9.1% | -6.0% | -6.3% | -8.9% | -3.8% | -1.2% | 1.6% | 1.6% | 0.8% | 0.6% |
| ROE | — | -12.9% | -8.7% | -9.3% | -14.4% | -0.8% | 0.6% | 1.6% | 0.8% | -0.2% | -3.8% |
Frequently asked questions
What is Neogenomics’s annual revenue?
$727M in fiscal 2025 and $788M over the twelve months to September 30, 2026.
How much profit does Neogenomics make?
Net income was -$108M in fiscal 2025 (net margin -14.9%).
Is Neogenomics’s revenue growing?
Yes: revenue rose 10.1% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.